<DOC>
	<DOCNO>NCT00430352</DOCNO>
	<brief_summary>This single arm study evaluate safety efficacy MabThera maintenance therapy follow MabThera-containing induction regimen first line relapse patient follicular non-Hodgkin 's lymphoma . All patient receive MabThera 375mg/m2 body surface area , intravenous infusion , every 8 week . The anticipated time study treatment 1-2 year , target sample size 500+ individual .</brief_summary>
	<brief_title>MAXIMA Study : A Study Maintenance Therapy With MabThera ( Rituximab ) Patients With Non-Hodgkin 's Lymphoma .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; histologically confirm grade 1 , 2 3a follicular nonHodgkin 's lymphoma ; patient receive adequate ( &gt; =8 cycle ) induction therapy MabThera first line treatment , treatment relapse disease ; demonstrate partial complete response induction therapy . stable progressive disease recent induction therapy ; transformation high grade lymphoma ; patient prior concomitant malignancy , except nonmelanoma skin cancer adequately treat situ cancer cervix .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>